Proteomics 2003

Laura Wood laura.wood at
Thu Aug 7 16:27:40 EST 2003

I enclose details of our latest proteomics report.

Proteomics technologies have dramatically accelerated the study of proteins, resulting in the discovery of thousands of potential biomarkers and drug targets. Further advances, primarily in mass spectrometry, are expected to increase the rate of discovery. The proteomics market grew from $1.1 billion in 2001 to almost $1.4 billion in 2002 and, based on first quarter numbers, the growth rate is continuing in 2003. But the success is creating a bottleneck. High-throughput and/or high-output technologies are used to discover potential biomarkers and drug targets, but the validation methods are low-throughput and low-output. For proteomics to continue its current growth rate, the industry needs new methods and technologies to speed validation. Fortunately, multiple emerging technologies are poised to meet this need. 

The report, Proteomics 2003, presents detailed interviews with proteomics experts, thorough evaluations of 75 leading proteomics companies in the United States and Europe, three scenarios for the future of the industry, and a quantitative market model. The analysis is based on extensive research that includes dozens of interviews with current and potential customers and with company representatives. 

Proteomics 2003 reveals the insights of experts regarding unmet needs and future directions of the industry. Despite the range of opinions and practices, the experts all agreed about the developing bottleneck. The report also evaluates the strengths and weaknesses of each of the proteomics companies, and assesses both opportunities and threats facing their products and services. Proteomics 2003 identifies the companies most likely to dominate specific market segments, as well as the companies most likely to play key supporting roles in moving technologies forward. 

Proteomics 2003 presents a pessimistic, a cautiously optimistic, and an optimistic scenario for the growth of the industry. Even in the worst case, the market holds its ground; in the best case, proteomics dramatically accelerates drug discovery and development and extends this success into diagnostics. 

Proteomics 2003 divides the market into the three different applications. The first is discovery and validation of drug targets and biomarkers, in which researchers use proteomics technologies to discover and, to a much lesser extent, to validate the roles of specific proteins in disease processes. The second application is drug development, in which researchers transform drug targets into potential therapeutics. The third application is clinical trials and diagnostics, in which scientists strive to use proteomics technologies to identify and monitor disease states and drug responses. 

At the same time, the report examines how each of these applications employs the four classes of proteomics technologies. (1) Mass spectrometry systems are used to detect proteins based on the charge/mass ratio of peptides, and to identify proteins by comparing this ratio to a database of predicted values. (2) Protein separation divides the proteome into manageable units. The primary methods are 2-D gel electrophoresis and chromatography. After separation, the proteins are commonly identified by mass spectrometry. (3) Parallelized screening methods analyze proteins in parallel, and generally have higher throughput than other proteomics methods. The primary technologies are based on beads or biochips. (4) Functional proteomics includes a family of innovative methods for high-output and/or high-throughput analysis of protein function. 

For a complete index of this report click on

Report Index:

Chapter 1: Executive Summary 8

Introduction 9
Applications 10
Interviews with Experts 11
Competitive Environment 12
State of the Market in 2003 13
Successes 13
Challenges 14
Scenarios 16
Market Size 17
Total 17
By Technology 18
By Applications 19

Chapter 2: Technology 20

Introduction 21
Output versus Throughput 22
Mass Spectrometry 23
Introduction 23
Ionization Methods 24
Mass Analysis Methods 25
Common Instrument Configurations 27
A Typical Proteomic Analysis 28
Quantitative Methods 29
Protein Separation 30
2-D Gel Electrophoresis 30
Chromatography 31
Parallelized Screening Methods 32
Protein Biochips 32
Bead-Based Methods 34
Functional Proteomics 35
Overview 35
Map 36

Chapter 3: Applications 37

Expression and Function 38
Target/Biomarker Discovery 39
Target/Biomarker Validation 40
Drug Development 42
Clinical Trials/ Diagnostics 45

Chapter 4: Interviews with Experts 47

Introduction 48
Successes 49
Challenges 50
The Looming Validation Bottleneck 51
Expert 1 52
Expert 2 56
Expert 3 59
Expert 4 62
Expert 5 65
Expert 6 66
Expert 7 68
Expert 8 70
Expert 9 72
Expert 10 74

Chapter 5: Company Evaluations 76

Mass Spectrometry 77
Agilent Technologies Inc. 78
Applied Biosystems Group 80
Bruker Daltonics, Inc. 82
PerkinElmer Life Sciences 84
Shimadzu Biotech 87
Target Discovery, Inc. 89
Thermo Finnigan 91
Waters Corporation 93

Protein Separation 95

Amersham Biosciences 96
Beckman Coulter, Inc. 98
Bio-Rad Laboratories, Inc. 100

Parallelized Screening Methods 105

Affibody AB 106
Archemix Corporation 107
Aspira Biosystems, Inc. 110
BD Biosciences 113
Biacore International AB 116
BioForce Nanosciences, Inc. 118
BioInvent International AB 121
Biosite Incorporated 123
Cambridge Antibody Technology Group plc 126
Ciphergen Biosystems, Inc. 128
CombiMatrix 131
Corning Incorporated Life Sciences 134
Discerna Ltd. 136
Domantis Limited 138
GeneScan Europe AG 139
HTS Biosystems, Inc. 142
Hypromatrix, Inc. 145
Jerini AG 147
Large Scale Biology Corporation 151
Eurogentec Proteomics GmbH 101
Proteome Systems Ltd. 103
LumiCyte, Inc. 154
Luminex Corporation 156
Molecular Staging Inc. 158
nanotype GmbH 160
NextGen Sciences Ltd. 163
Pepscan Systems BV 167
Phylos, Inc. 170
Procognia Ltd. 172
Protagen AG 174
ProteinOne Inc. 177
Protiveris Inc. 179
Protometrix, Inc. 181
Randox Laboratories Ltd. 185
SomaLogic, Inc. 187
TeleChem International, Inc. 190
VBC-GENOMICS Bioscience Research GmbH 193
Zeptosens AG 195
Zyomyx, Inc. 198
LumiCyte, Inc. 154
Luminex Corporation 156
Molecular Staging Inc. 158
nanotype GmbH 160
NextGen Sciences Ltd. 163
Pepscan Systems BV 167
Phylos, Inc. 170
Procognia Ltd. 172
Protagen AG 174
ProteinOne Inc. 177
Protiveris Inc. 179
Protometrix, Inc. 181
Randox Laboratories Ltd. 185
SomaLogic, Inc. 187
TeleChem International, Inc. 190
VBC-GENOMICS Bioscience Research GmbH 193
Zeptosens AG 195
Zyomyx, Inc. 198

Chapter 6: Market Model 258

State of the Market in 2003 259
Successes 259
Challenges 260
Scenarios 262
Total Market 263
Companies 263
Size 267
Market Model Methodology 268
Research and Analysis 268
Quantitation 269
Market Segmentation 270
Market Definitions 271
Market Inclusions and Exclusions 272
Market By Technology 273
Drivers 273
Size and Shares 274
Market By Data Type 275
Drivers 275
Size and Shares 276
Market By Applications 277
Drivers 277
Size and Shares 278

Report Pricing:

Hard Copy   EUR 5,297
Electronic   EUR 6,153
Site Licence   EUR 6,153


Order online: To order this report please click on
Order via email: mailto:orders at
Order via fax-back form: Click on Fax to +353 14957318
Order via post: Click on
Mail to Research and Markets Ltd., Guinness Centre, Taylors Lane, Dublin 8, Ireland

Related Reports Available from Research & Markets Ltd:

Post Genome Project Era Proteomics R&D Competition -
Functional Proteomics and Emerging Bio-IT Market -
U.S. Bio-Computing IT Market Bio-Computing + Pharmaceutical Companies, The Fusion of Computing and Drug Discovery: Technologies, Products, Vendors, Opportunities and Market Forecasts  -
Toxicogenomics and Related Approaches: The Promise of Safer, Smarter Drug Development -
Profiting from Proteomics: Entering the Age of High-Throughput -
Proteomics: Analysis of Selected Emerging Technologies -
Protein Science Benchmarking Study -
Advances in Lead Optimization, Accelerating Drug Discovery and Development -
Protein Kinases: Technologies and Opportunities for Drug Discovery -
Structural Proteomics: High-Throughput Approaches Fuel Drug Discovery & Development -
Proteomics Survey Report 2003 -
Proteomics and Bioethics: The Future of the Human Genome -
Genomics -
Advances in Lead Optimization, Accelerating Drug Discovery and Development -
Biotech & Genetics Industry Almanac 2003-2004 -

Click on for details.

Thank you for your consideration.

Kind Regards,

Laura Wood
Senior Manager
Research and Markets Ltd
laura.wood at

Proteomics 2003
Publisher Name: Select Biosciences Ltd
Date Published: 07/07/03
Number of Pages: 278
Category: Proteomics

Subscribe: Click on You can subscribe free for regular details on new research in your sector.

If you no longer wish to receive our market research updates, please reply to this message with "Suppression Request" as the subject line, or email a blank email to suppressed at or access our unsubscribe page at:


More information about the Dros mailing list